Lower esophageal cancer/esophagogastric junction cancer
Conditions
Interventions
Observation group (accepted neo-AICIT(Neoadjuvant arterial Infusion chemotherapy combined with immunotherapy )):NA
Sponsors
Xiamen Humanity Hospital affiliated to Fujian Medical University
Eligibility
Sex/Gender
All
Age
20 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patients were diagnosed with cT3N0-2M0 stage III lower esophageal cancer or esophagogastric junction cancer by gastroscopic biopsy, PET-CT and other auxiliary examinations; 2. Accept neo-AICIT; (3) radical surgery for esophageal cancer after neoadjuvant therapy; 4. Postoperative immune monotherapy was maintained for 1 year.
Exclusion criteria
Exclusion criteria: 1. Variation of feeding arteries in the lower segment of esophagus or cardia during interventional operation has a great impact on the therapeutic effect; 2. After receiving =2 courses of neoadjuvant treatment, the treatment was given up and the treatment effect was not evaluated; 3. After neoadjuvant therapy, patients refused to evaluate the treatment effect or were lost to follow-up for various reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of neoadjuvant therapy;Tumor regression grade(TRG); | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications of interventional procedures;Adverse drug reactions;Surgical Complications; | — |
Countries
China
Contacts
Public ContactQingjie Yang
Xiamen Humanity Hospital affiliated to Fujian Medical University
Outcome results
None listed